| Submission declined on 4 December 2023 by Chetsford (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 16 June 2023 by Turnagra (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by Turnagra 11 months ago. | |
| Submission declined on 9 February 2023 by CNMall41 (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. Declined by CNMall41 15 months ago. | |
Comment: I'm not convinced by the sources that Tooman is notable enough for an article. The only sources which discuss him as a person seem to be only articles because the company is notable, not Tooman specifically. Before being expanded, there would need to be more sources in this space and demonstrate that Tooman himself is notable rather than just who he works for. Turnagra (talk) 23:39, 16 June 2023 (UTC)
Craig Tooman (born c. 1965) is a pharmaceutical executive who has held several CEO and CFO positions in the biotechnology space.[1]
Education edit
Tooman obtained a B.A. in economics from Kalamazoo College in Michigan. He earned an MBA from the University of Chicago.[2]
Career edit
Tooman's career has been marked by repeated involvement raising funds and brokering pharmaceutical M&A deals,[3] including Aranta Therapeutics merger with Elanco;[4] Ilex Oncology's merger with Genzyme;[5] and Enzon Pharmaceuticals's sale of its specialty pharmaceutical division to Sigma-tau, an Italian pharmaceutical group in 2009.[6] Over his thirty year career, Tooman has raised $9 billion in various IPOs, mergers and joint ventures.[7]
In February 2022, Tooman was promoted from CFO to CEO at Silence Therapeutics (NASDAQ: SLN), which designs and develops siRNAs (short interfering RNAs).[8] On January 12, 2023, at the 41st Annual J.P. Morgan Healthcare Conference, Tooman revealed the company has begun phase 2 testing for SLN360 and is readying further steps for a second proprietary siRNA therapy, SLN124. He also detailed three separate partner deals with AstraZeneca, Mallinckrodt, and Hansoh Pharma with $7.5B in potential milestones.[9]
[10] Innovation edit
In 2012, Tooman was named the first Entrepreneur-in-Residence at The Cancer Prevention and Research Institute of Texas (CPRIT), receiving a grant as part of the program “to recruit life science entrepreneurs to Texas.”[11]
Awards edit
- 1999 - William Upjohn Prize[12] - highest recognition for an employee in The Upjohn Company
- 2001 - PRWeek Investor Campaign Relations Campaign of the Year[13]
- 2001 - IABC Gold Quill Awards; 2001 Investor/Shareholder Relations Excellence Award
- 2012- Entrepreneur-in-Residence at The Cancer Prevention and Research Institute of Texas[14]
References edit
- ^ "Silence Therapeutics announces the appointment of Craig Tooman as its chief financial officer". Proactiveinvestors UK. 2021-01-06. Retrieved 2023-02-10.
- ^ "Enzon Pharmaceuticals, Inc". sec.gov. Retrieved 2023-02-08.
- ^ "Pursuing Hybrid Funding Models With Silence Therapeutics' Craig Tooman". lifescienceleader.com/. Life Science Leader Magazine.
- ^ "Elanco Announces Agreement to Acquire Aratana Therapeutics; Completes Oncology Development Agreement with VetDC, Creates Specialty Veterinary Business Focus". businesswire.com. 2019-04-26. Retrieved 2023-02-08.
- ^ "Week at a Glance: ILEX Oncology". The Business Journals. Retrieved 2023-02-10.
- ^ "Sigma-tau Acquires Enzon Drug Business". cen.acs.org. Retrieved 2023-02-08.
- ^ "The Innovating CEO". thevanguardnetwork.com. Retrieved 2023-03-12.
- ^ "Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer". Yahoo!. Retrieved 2023-02-10.
- ^ MarketScreener (12 January 2023). "Transcript : Silence Therapeutics plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 09:45 AM | MarketScreener". www.marketscreener.com. Retrieved 2023-02-08.
- ^ "Enzon Pharmaceuticals, Inc". sec.gov. Retrieved 2023-02-08.
- ^ "CPRIT program seeks entrepreneurs to create Texas oncology companies". The Business Journals. Retrieved 2023-02-10.
- ^ "1938-2003 List of Upjohn Awards". upjohn.net. Retrieved 2023-02-08.
- ^ "PR WEEK AWARDS 2001: Campaign - Investor/Financial Relations Campaign of the Year 2001. Sponsored by Weber Shandwick Worldwide". prweek.com. Retrieved 2023-02-08.
- ^ "CPRIT program seeks entrepreneurs to create Texas oncology companies". The Business Journals. Retrieved 2023-02-08.